Rachel Humphrey, Director at Pyxis Oncology, Inc. (PYXS), sold 30,792 shares at $0.97 ($32K) on 2025-04-14, disclosed to the SEC on 2026-03-25.
Scheduled sale ($32k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $0.97 | 1,400 | $1K | 4.3% |
| 2 | $0.97 | 1,400 | $1K | 4.3% |
| 3 | $0.97 | 200 | $194 | 0.6% |
| 4 | $1.03 | 13,896 | $14K | 45.3% |
| 5 | $1.03 | 13,896 | $14K | 45.5% |
| Total | $1.03 avg | 30,792 |
| $32K |
| 100% |
| Filing → |